^
    14d
    Cardiac HDAC3 Disruption Contributes to HDAC Inhibitor-Induced QT Prolongation. (PubMed, Cells)
    Moreover, a single dose of HDAC inhibitors, romidepsin or mocetinostat, caused reversible QT prolongation in mice. Consistent with these findings, HDAC inhibitor treatment altered the expression of potassium channel genes, with a predominant downregulation of multiple Kcn family members, including Kcnq1, Kcnh2, and Kcnip2. These findings establish HDAC3 enzymatic activity as a key regulator of cardiac repolarization and provide mechanistic insight into HDAC inhibitor-associated cardiotoxicity.
    Journal
    |
    KCNQ1OT1 (KCNQ1 Opposite Strand/Antisense Transcript 1) • HDAC3 (Histone Deacetylase 3) • KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2)
    |
    romidepsin • mocetinostat (MGCD0103)
    1m
    Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells. (PubMed, Bioorg Chem)
    In vivo xenograft models confirmed that the combination of RO and ADA significantly reduced tumor growth. These findings suggest that RO and ADA act synergistically against KRAS-mutant tumors by suppressing NRF2, supporting their potential as a targeted combination strategy for KRAS-driven cancers.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KRAS mutation
    |
    Krazati (adagrasib) • romidepsin
    1m
    Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov)
    P1/2, N=11, Terminated, University of Michigan Rogel Cancer Center | Active, not recruiting --> Terminated; Lack of accrual
    Trial termination
    |
    Ninlaro (ixazomib) • romidepsin
    1m
    PTCL13: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=89, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Completed --> Active, not recruiting
    Enrollment closed
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • romidepsin
    2ms
    Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas (clinicaltrials.gov)
    P1, N=114, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    bortezomib • Copiktra (duvelisib) • romidepsin
    2ms
    Oracle: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (clinicaltrials.gov)
    P3, N=86, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion • Trial completion date
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    gemcitabine • bendamustine • romidepsin • Onureg (azacitidine oral)
    2ms
    PTCL13: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=89, Completed, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Completed
    Trial completion
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • romidepsin
    2ms
    Targeting histone deacetylation, cell cycle regulators and heat shock proteins as novel therapeutic strategies for penile cancers. (PubMed, NPJ Precis Oncol)
    A paclitaxel, ifosfamide, and cisplatin-based regimen achieves response rates around 65%...Compared to standard chemotherapy (e.g. cisplatin, 5-FU, ifosfamide, irinotecan), treatment with romidepsin, quisinostat (HDAC inhibitors (i)), palbociclib (CDK4/6i), or 17-AAG and PU-H71 (HSP90i) reduced cell viability, induced apoptosis, and led to G2 / M cell cycle arrest in most PeCa cells. This research underscores the therapeutic potential of using HDAC, CDK4/6, and HSP90 inhibitors for PeCa management and reveals additional promising targets and biomarkers for future strategies.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    cisplatin • Ibrance (palbociclib) • paclitaxel • 5-fluorouracil • ifosfamide • irinotecan • romidepsin • quisinostat (JNJ 26481585) • zelavespib intravenous (PU-H71 IV)
    3ms
    Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents (clinicaltrials.gov)
    P1, N=12, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended
    Trial suspension
    |
    Imfinzi (durvalumab) • romidepsin
    4ms
    Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (clinicaltrials.gov)
    P1, N=26, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    TNFRSF8 positive
    |
    lenalidomide • romidepsin • Onureg (azacitidine oral)
    5ms
    SYNACTHIV: Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (clinicaltrials.gov)
    P1, N=9, Completed, ANRS, Emerging Infectious Diseases | Recruiting --> Completed | N=15 --> 9 | Trial completion date: Apr 2026 --> Dec 2025 | Trial primary completion date: Apr 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    decitabine • romidepsin
    5ms
    EPI-SauriCas9-based mouse ovarian cancer models recapitulating pten deletion in patients. (PubMed, Commun Biol)
    High-throughput drug screening identifies FK228 and thioguanine as promising therapeutic candidates, both of which show in vivo efficacy and are validated in PTEN-deleted organoids. Together, these results establish MEPP as a platform for studying PTEN-deleted ovarian cancer and provide a strategy for generating clinically relevant tumor models through targeted gene editing.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
    |
    TP53 mutation • PTEN deletion • TP53 deletion
    |
    romidepsin • thioguanine